Roche to complete acquisition of U.S. biopharma company Poseida Roche on Wednesday said it planned to complete its purchase of U.S. biopharmaceutical company Poseida Therapeutics via its subsidiary Blue Giant Acquisition Corp. Roche said it has accepted for payment nearly 65 million shares in Poseida - equivalent to 66% of the California company's stock - which had been tendered by shareholders at a price of $9 per share, with additional contingent payment of up to $4 per share.
Roche plans to finalize its acquisition of Poseida Therapeutics through its subsidiary, Blue Giant Acquisition Corp. The company has accepted nearly 65 million shares, representing 66% of Poseida's stock, at a price of $9 per share, with a potential additional payment of up to $4 per share.
ZURICH (Reuters) - Roche on Wednesday said it planned to complete its purchase of U.S. biopharmaceutical company Poseida Therapeutics via its subsidiary Blue Giant Acquisition Corp.
Roche said it has accepted for payment nearly 65 million shares in Poseida - equivalent to 66% of the California company's stock - which had been tendered by shareholders at a price of $9 per share, with additional contingent payment of up to $4 per share.
(Reporting by John Revill, editing by Rachel More)
